What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to publicly disclose Pfizer Inc.'s updated earnings projections for 2003 and 2004, which were provided in a press release on September 3, 2003. This information is being shared with investors in advance of upcoming conference presentations.

Why did Pfizer provide earnings projections on both an adjusted and GAAP basis?

Providing earnings projections on both an adjusted and GAAP basis allows investors to see the company's expected financial performance under two different reporting methods. Adjusted earnings often exclude certain items that management believes are not indicative of ongoing operational performance, while GAAP earnings provide the standard, audited financial picture. This dual reporting offers a more comprehensive view for investors.

When can investors find more details about these earnings projections?

More details about these earnings projections can be found in the press release dated September 3, 2003, which is included as Exhibit 99 to this 8-K filing. The press release was issued in conjunction with upcoming investor conference presentations, suggesting further discussion at those events.

What does this filing imply for Pfizer's financial outlook?

This filing implies that Pfizer is actively managing investor expectations by providing updated forward-looking financial guidance. It suggests that the company is ready to discuss its performance and future prospects with the investment community, and these projections are a key component of that communication.

PFE 8-K SEC Disclosure

Summary

Pfizer Inc. (PFE) filed an 8-K on September 4, 2003, reporting on a press release issued the previous day, September 3, 2003. This press release provided crucial updated earnings projections for both the full year 2003 and the upcoming year 2004. Investors should note that these projections were presented on both an adjusted basis and according to Generally Accepted Accounting Principles (GAAP). These updated financial outlooks were released in anticipation of upcoming investor conference presentations. This type of disclosure is significant as it offers a forward-looking view of the company's expected financial performance, allowing investors to assess future profitability and make more informed investment decisions. The provision of both adjusted and GAAP figures enables a comprehensive understanding of Pfizer's financial guidance, accounting for potential non-recurring items versus the standard reporting framework.

Key Highlights

1Pfizer issued a press release on September 3, 2003, providing updated earnings projections.
2Projections cover both the full year 2003 and the upcoming year 2004.
3Earnings guidance was provided on both an adjusted and a GAAP basis.
4The disclosure was made in conjunction with upcoming investor conference presentations.
5This filing signals an important update to the company's financial outlook for investors.
6The press release is furnished as an exhibit to the 8-K filing.

PFIZER INC 8-K Report (Sep 4, 2003)

Summary

Key Highlights

Frequently Asked Questions